Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namodenoson in NAFLD and NASH
NCT02927314Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Nov 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of namodenoson in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Can-Fite BioPharma Ltd. Primary endpoints: Serum Alanine Aminotransferase at 12 weeks and Magnetic Resonance Imaging-Determined Hepatic Steatosis at 12 weeks. Started Nov 2017; status: completed.
02
Drugs
namodenoson
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02927314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927314.